Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Preveceutical Medical Inc (OP: PRVCF )

0.0148 +0.0002 (+1.37%)
Streaming Delayed Price Updated: 12:51 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 211,616
Open 0.0134
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0146
Today's Range 0.0111 - 0.0185
52wk Range 0.0110 - 0.0250
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
PreveCeutical Medical - Sol-Gel and Uses thereof Patent Update
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2023) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF)... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
-3.27%
-3.27%
1 Month
-12.94%
-12.94%
3 Month
+0.68%
+0.68%
6 Month
-24.49%
-24.49%
1 Year
-38.84%
-38.84%

More News

Read More
PreveCeutical Medical Launches Clinical Artificial Intelligence Division
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain
Via Newsfile
PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
Via Newsfile
PreveCeutical - International Filing of Thermoresponsive Sol-Gels Containing Cannabinoids & Uses Thereof
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Appointment of C. Evan Ballantyne to PreveCeutical's Board of Directors
Via Newsfile
PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development
Via Newsfile
PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds
Via Newsfile
Topics Bonds Intellectual Property
Exposures Debt Markets Intellectual Property
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Via Newsfile
Topics Bonds Intellectual Property
Exposures Debt Markets Intellectual Property
PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals
Via Newsfile
PreveCeutical Signs Intercompany Sol-Gel License Agreement
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Appointment of Sachin Nanavati to PreveCeutical's Board of Directors
Via Newsfile
PreveCeutical Files International Patent Application for Sol-Gel Cannabinoid Formulation for Antiviral Use
Via Newsfile
Topics Cannabis Death Intellectual Property
Exposures COVID-19 Cannabis Death
PreveCeutical Signs License Agreement for Exclusive Rights to Use UniQuest's Sol-Gel Technology for Delivery of Cannabinoids
Via Newsfile
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
PreveCeutical Files International Patent Application for its Dynorphin Peptides
Via Newsfile
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
PreveCeutical Provides Corporate Update
Via Newsfile
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.